Navigation Links
Risk for patients in the intensive care unit clearly reduced
Date:3/10/2010

To get life-threatening diseases under control, patients in the intensive care unit usually are administered many medications at the same time. Even for experts, it is difficult to keep track of the variety of possible side effects and interactions. The team headed by Dr. Thilo Bertsche, director of the cooperation unit for clinical pharmacy at Heidelberg University Hospital, has now shown that physicians can reduce serious events resulting from drug interactions by about half with the help of the "AiDKlinik" drug information system. The results of the study were published in the prestigious journal "Intensive Care Medicine".

One of the few effective drug information systems in the world

"We previously verifiably improved physician's prescriptions with our "AiDKlinik" tool and showed that no new errors were introduced. However, we have now proven that laboratory values and clinical findings are also changed. Not many systems in the world can maintain that they have been able to reduce clinically relevant events due to drug interactions by almost half," says Professor Dr. Walter E. Haefeli, Medical Director of the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital.

Erroneous prescriptions, interactions not taken into account, contraindications, or restrictions on use are often the cause of avoidable adverse drug effects. The "AiDKlinik" drug information system developed at the hospital helps to reduce such undesired events. While the condition of patients in the ICU frequently requires that they be given certain drugs despite known interactions, the goal is to prevent clinically relevant events that could endanger the patients.

Half as many risk situations for ICU patients

Data from 265 patients were examined for the study in an intensive care unit at Heidelberg University Hospital. The study included only patients who were given eight or nine drugs simultaneously. On the second day after admission, the prescribed medication was checked using the drug information system. At the next rounds, the physicians responsible for the patient were given a report on potential drug interactions and, if necessary, concrete recommendations to avoid clinical effects.

Using this procedure, the adverse events in connection with drug interactions were reduced by 43 percent. Some of the most critical events, such as changes in the ECG and electrolyte imbalances, which can lead to severe arrhythmia, were reduced by 64 percent and 80 percent respectively. In addition, fewer patients needed additional drugs to treat side effects.

"AiDKlinik" a development from hospital practice

The "AiDKlinik" drug information system was developed in recent years by the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital in conjunction with the hospital pharmacy and Medizinische Medien Informations GmbH (MMI, Neu-Isenburg) and has since been continuously expanded. It is an Internet-based electronic guideline that can be used by hospitals and practices. Numerous relevant patient data such as age, renal function, pregnancy, etc. are included in information processing. The information system currently includes around 64,000 drugs and is implemented in the entire university hospital. The information stems from the Pharmindex database, issued by the medical publishing house Medizinische Medien Informations GmbH and is updated every 14 days.


'/>"/>

Contact: Dr. Thilo Bertsche
klinischepharmazie@med.uni-heidelberg.de
062-215-639-537
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Risk for patients in the intensive care unit clearly reduced
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: